Explore evidence

15.5 %The pooled HCV prevalence for the high-risk group in Kenya was 15.5%.

Kenyahépatite Cpublished 2024Journal of epidemiology and global healthPubMeddocument of 8 observations

647 USD_per_DALY_averterThe intervention was not cost-effective at the opportunity cost-based cost-effectiveness threshold of $647 per disability-adjusted life-year averted.

Kenyahépatite Cpublished 2022Addiction (Abingdon, England)PubMeddocument of 4 observations

94 %HCV genotype 1 and genotype 4 together accounted for 94% of cases in Kenya.

KenyaHCV genotype 1 · HCV genotype 4 · hépatite Cpublished 2024Journal of epidemiology and global healthPubMeddocument of 8 observations

90,668 samplesA total of 29 studies with a sample size of 90,668 met the inclusion criteria for the HCV review in Kenya.

Kenyahépatite Cpublished 2024Journal of epidemiology and global healthPubMeddocument of 8 observations

AFRICOS participants had significantly lower rates of hepatitis C coinfection compared to DC Cohort participants.

Kenyahépatite Cpublished 2022PloS onePubMeddocument of 13 observations

3.4 %The pooled HCV prevalence for the intermediate-risk group in Kenya was 3.4%.

Kenyahépatite Cpublished 2024Journal of epidemiology and global healthPubMeddocument of 8 observations